Författare: Sandström Thomas, Hedlin Gunilla
Titel: Anti-IgE blockerar central astmamekanism (serie: Tema immunterapi vid astma/allergi) 2008 nr 26 sid 1933-4
Ämnesord:
Antiastmatiska medel
Monoklonala antikroppar
Astma
Sök liknande artiklar
Referenser:
1.Rabe KF, Adachi M, Lai CK et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114:40-7.
2.Partridge MR, van der Molen T, Myrseth SE et al. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13.
3.Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836-44.
4.Prussin C, Griffith DT, Boesel KM et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003;112:1147-54.
5.Djukanovi_ R, Wilson SJ, Kraft M et al. The effects of anti-IgE (omalizumab) treatment on airways inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170(6):583-93
6.Plewako H, Arvidsson M, Petruson K et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol. 2002;110(1):68-71.
7.MacGlashan DW, Bochner BS, Adelman DC et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438-45.
8.Humbert M, Beasley R, Ayres J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16.
9.Ayres JG, Higgins B, Chilvers ER et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59: 701-708.
10.Vignola AM, Humbert M, Bousquet J et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis (SOLAR). Allergy 2004;59: 709-717.
11.Bussey W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108: 184-190.
12.Solèr M, Matz J, Townley R et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18: 254-261
13.Holgate ST, Chuchalin AG, Hébert J et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34: 632-638.
14.Bousquet, J, Cabrera P, Berkman N et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60 (3), 302-308.
15.Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol. 2004;114(2):265-9.
16.Dewilde S, Turk F, Tambour M et al. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin. 2006;22:1765-76.
17.Berger W, Gupta N, McAlary M et al. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol. 2003;91(2):182-8.
18.Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:E36.
19.Corren J, Casale T, Lanier B, Buhl, R, Holgate ST, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy, in press.
1933 |
1934 |
